ALTEOGEN Inc.

KOSDAQ:A196170 Stock Report

Market Cap: ₩20.1t

ALTEOGEN Past Earnings Performance

Past criteria checks 5/6

ALTEOGEN has been growing earnings at an average annual rate of 59.2%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 28.1% per year. ALTEOGEN's return on equity is 27.2%, and it has net margins of 82.1%.

Key information

59.18%

Earnings growth rate

58.13%

EPS growth rate

Biotechs Industry Growth11.70%
Revenue growth rate28.07%
Return on equity27.19%
Net Margin82.07%
Last Earnings Update31 Mar 2025

Recent past performance updates

Statutory Earnings May Not Be The Best Way To Understand ALTEOGEN's (KOSDAQ:196170) True Position

Mar 29
Statutory Earnings May Not Be The Best Way To Understand ALTEOGEN's (KOSDAQ:196170) True Position

Recent updates

Estimating The Fair Value Of ALTEOGEN Inc. (KOSDAQ:196170)

Jun 26
Estimating The Fair Value Of ALTEOGEN Inc. (KOSDAQ:196170)

Is Now The Time To Put ALTEOGEN (KOSDAQ:196170) On Your Watchlist?

Jun 02
Is Now The Time To Put ALTEOGEN (KOSDAQ:196170) On Your Watchlist?

Statutory Earnings May Not Be The Best Way To Understand ALTEOGEN's (KOSDAQ:196170) True Position

Mar 29
Statutory Earnings May Not Be The Best Way To Understand ALTEOGEN's (KOSDAQ:196170) True Position

Revenue & Expenses Breakdown

How ALTEOGEN makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A196170 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 25151,650124,46113,53023,803
31 Dec 24102,85562,25212,74824,550
30 Sep 2474,375-2,90612,58423,855
30 Jun 2490,788-1,28212,70428,641
31 Mar 24121,08725,54213,95523,635
31 Dec 2396,523-3,37214,46825,306
30 Sep 2385,0366,45914,42121,286
30 Jun 2369,1547,86515,08317,695
31 Mar 2332,199-21,79814,92722,559
31 Dec 2228,806-8,14614,23418,660
30 Sep 2232,2921,36714,41212,422
30 Jun 2233,065-22315,1074,731
31 Mar 2233,807-1,24322,7091,165
31 Dec 2138,746-6,27512,7137,480
30 Sep 2129,498-38,97112,25114,481
30 Jun 2137,316-26,97512,13414,481
31 Mar 2144,433-17,7483,17915,350
31 Dec 2042,426-15,82210,5377,691
30 Sep 2051,93515,4249,5136,308
30 Jun 2043,4209,0407,8866,308
31 Mar 2035,2425,0016,9665,566
31 Dec 1929,229-7056,4186,457
30 Sep 1918,012-7,9005,6475,671
30 Jun 1915,796-8,5746,1105,671
31 Mar 1913,473-8,0783,9786,718
31 Dec 1813,703-6,8723,3555,962
30 Sep 1813,079-11,7762,6157,983
30 Jun 1812,610-9,9457947,983
31 Mar 1811,788-10,3321,7906,394
31 Dec 1712,104-7,4492,3164,654
30 Sep 1711,815-2,8372,3053,631
30 Jun 1711,567-2,8712,3143,631
31 Mar 1710,569-1,9612,2573,765
31 Dec 166,844-3,5871,8793,976
30 Sep 166,088-1,4811,6033,323
30 Jun 164,213-2018913,323
31 Mar 163,634-1365992,719
31 Dec 154,7271,2081,3331,947
30 Sep 154,5853371,3751,982
30 Jun 155,6863201,2071,982
31 Mar 156,8741,2091,4111,906
31 Dec 147,0439311,2851,837
30 Sep 146,7531,1581,2941,534

Quality Earnings: A196170 has a high level of non-cash earnings.

Growing Profit Margin: A196170's current net profit margins (82.1%) are higher than last year (21.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A196170's earnings have grown significantly by 59.2% per year over the past 5 years.

Accelerating Growth: A196170's earnings growth over the past year (387.3%) exceeds its 5-year average (59.2% per year).

Earnings vs Industry: A196170 earnings growth over the past year (387.3%) exceeded the Biotechs industry 47.8%.

Return on Equity

High ROE: A196170's Return on Equity (27.2%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/07 14:50
End of Day Share Price 2025/07/07 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ALTEOGEN Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hyerin LeeDAOL Investment & Securities Co., Ltd.
null nullDBS Bank Ltd
Haesoon KwonEugene Investment & Securities Co Ltd.